Table of Contents Author Guidelines Submit a Manuscript
Journal of Osteoporosis
Volume 2017, Article ID 3710959, 8 pages
https://doi.org/10.1155/2017/3710959
Review Article

A Review on the Relationship between Aspirin and Bone Health

Department of Pharmacology, Universiti Kebangsaan Malaysia Medical Centre, Cheras, Kuala Lumpur, Malaysia

Correspondence should be addressed to Kok-Yong Chin; ym.ude.mku.mkupp@gnoykoknihc

Received 25 August 2016; Accepted 21 December 2016; Published 9 January 2017

Academic Editor: Merry Jo Oursler

Copyright © 2017 Kok-Yong Chin. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. L. J. Raggatt and N. C. Partridge, “Cellular and molecular mechanisms of bone remodeling,” Journal of Biological Chemistry, vol. 285, no. 33, pp. 25103–25108, 2010. View at Publisher · View at Google Scholar · View at Scopus
  2. A. E. Kearns, S. Khosla, and P. J. Kostenuik, “Receptor activator of nuclear factor κB ligand and osteoprotegerin regulation of bone remodeling in health and disease,” Endocrine Reviews, vol. 29, no. 2, pp. 155–192, 2008. View at Publisher · View at Google Scholar · View at Scopus
  3. D. J. Hadjidakis and I. I. Androulakis, “Bone remodeling,” Annals of the New York Academy of Sciences, vol. 1092, pp. 385–396, 2006. View at Publisher · View at Google Scholar · View at Scopus
  4. L. G. Raisz, “Potential impact of selective cyclooxygenase-2 inhibitors on bone metabolism in health and disease,” The American Journal of Medicine, vol. 110, no. 3, supplement 1, pp. 43–45, 2001. View at Publisher · View at Google Scholar · View at Scopus
  5. D. Agas, L. Marchetti, M. Capitani, and M. G. Sabbieti, “The dual face of parathyroid hormone and prostaglandins in the osteoimmune system,” American Journal of Physiology—Endocrinology and Metabolism, vol. 305, no. 10, pp. E1185–E1194, 2013. View at Publisher · View at Google Scholar · View at Scopus
  6. K. A. Blackwell, L. G. Raisz, and C. C. Pilbeam, “Prostaglandins in bone: bad cop, good cop?” Trends in Endocrinology and Metabolism, vol. 21, no. 5, pp. 294–301, 2010. View at Publisher · View at Google Scholar · View at Scopus
  7. H. Liu, W. Li, Y. Liu, X. Zhang, and Y. Zhou, “Co-administration of aspirin and allogeneic adipose-derived stromal cells attenuates bone loss in ovariectomized rats through the anti-inflammatory and chemotactic abilities of aspirin,” Stem Cell Research and Therapy, vol. 6, no. 1, article no. 200, 2015. View at Publisher · View at Google Scholar · View at Scopus
  8. K. Suda, N. Udagawa, N. Sato et al., “Suppression of osteoprotegerin expression by prostaglandin e2 is crucially involved in lipopolysaccharide-induced osteoclast formation,” Journal of Immunology, vol. 172, no. 4, pp. 2504–2510, 2004. View at Publisher · View at Google Scholar · View at Scopus
  9. Y. Zhou, D. M. Boudreau, and A. N. Freedman, “Trends in the use of aspirin and nonsteroidal anti-inflammatory drugs in the general U.S. population,” Pharmacoepidemiology and Drug Safety, vol. 23, no. 1, pp. 43–50, 2014. View at Publisher · View at Google Scholar · View at Scopus
  10. B. Cheng, Y. Kato, S. Zhao et al., “PGE2 is essential for gap junction-mediated Intercellular communication between osteocyte-like MLO-Y4 cells in response to mechanical strain,” Endocrinology, vol. 142, no. 8, pp. 3464–3473, 2001. View at Publisher · View at Google Scholar · View at Scopus
  11. V. Fuster and J. M. Sweeny, “Aspirin: a historical and contemporary therapeutic overview,” Circulation, vol. 123, no. 7, pp. 768–778, 2011. View at Publisher · View at Google Scholar · View at Scopus
  12. E. V. Paez Espinosa, J. P. Murad, and F. T. Khasawneh, “Aspirin: pharmacology and clinical applications,” Thrombosis, vol. 2012, Article ID 173124, 15 pages, 2012. View at Publisher · View at Google Scholar
  13. D. E. Furst, R. W. Ulrich, and S. Prakash, “Nonsteroidal anti-inflammatory drugs, disease-modifying antirheumatic drugs, nonopioid analgesics, & drugs used in gout,” in Basic and Clinical Pharmacology, B. G. Katzung, S. B. Masters, and A. J. Trevor, Eds., chapter 36, McGraw-Hill, New York, NY, USA, 12th edition, 2012. View at Google Scholar
  14. K. Bibbins-Domingo, D. C. Grossman, S. J. Curry et al., “Aspirin use for the primary prevention of cardiovascular disease and colorectal cancer: U.S. preventive services task force recommendation statement,” Annals of Internal Medicine, vol. 164, no. 12, pp. 836–845, 2016. View at Publisher · View at Google Scholar · View at Scopus
  15. S. P. Dehmer, M. V. Maciosek, T. J. Flottemesch, A. B. LaFrance, and E. P. Whitlock, “Aspirin for the primary prevention of cardiovascular disease and colorectal cancer: a decision analysis for the U.S. preventive services task force,” Annals of Internal Medicine, vol. 164, no. 12, pp. 777–786, 2016. View at Publisher · View at Google Scholar · View at Scopus
  16. X. Feng and J. M. McDonald, “Disorders of bone remodeling,” Annual Review of Pathology: Mechanisms of Disease, vol. 6, pp. 121–145, 2011. View at Publisher · View at Google Scholar · View at Scopus
  17. A. Papaioannou, C. C. Kennedy, G. Ioannidis et al., “The impact of incident fractures on health-related quality of life: 5 years of data from the Canadian multicentre osteoporosis study,” Osteoporosis International, vol. 20, no. 5, pp. 703–714, 2009. View at Publisher · View at Google Scholar · View at Scopus
  18. C. L. Ekegren, E. R. Edwards, R. Page et al., “Twelve-month mortality and functional outcomes in hip fracture patients under 65 years of age,” Injury, vol. 47, no. 10, pp. 2182–2188, 2016. View at Publisher · View at Google Scholar
  19. S. H. Lee, I. J. Chen, Y. H. Li, C. Y. Fan Chiang, C. H. Chang, and P. H. Hsieh, “Incidence of second hip fractures and associated mortality in taiwan: a nationwide population-based study of 95,484 patients during 2006–2010,” Acta Orthopaedica et Traumatologica Turcica, vol. 50, no. 4, pp. 437–442, 2016. View at Google Scholar
  20. Y. P. Zeng, C. Yang, Y. Li et al., “Aspirin inhibits osteoclastogenesis by suppressing the activation of NF-κB and MAPKs in RANKL-induced RAW264.7 cells,” Molecular Medicine Reports, vol. 14, no. 3, pp. 1957–1962, 2016. View at Publisher · View at Google Scholar
  21. T. Lawrence, “The nuclear factor NF-κB pathway in inflammation,” Cold Spring Harbor Perspectives in Biology, vol. 1, no. 6, Article ID a001651, 2009. View at Publisher · View at Google Scholar · View at Scopus
  22. P. P. Tak and G. S. Firestein, “NF-κB: a key role in inflammatory diseases,” The Journal of Clinical Investigation, vol. 107, no. 1, pp. 7–11, 2001. View at Publisher · View at Google Scholar · View at Scopus
  23. T. Yamaza, Y. Miura, Y. Bi et al., “Pharmacologic stem cell based intervention as a new approach to osteoporosis treatment in rodents,” PLoS ONE, vol. 3, no. 7, article 2615, 2008. View at Publisher · View at Google Scholar · View at Scopus
  24. D. J. Waters, D. D. Caywood, G. J. Trachte, R. T. Turner, and S. F. Hodgson, “Immobilization increases bone prostaglandin E: effect of acetylsalicylic acid on disuse osteoporosis studied in dogs,” Acta Orthopaedica, vol. 62, no. 3, pp. 238–243, 1991. View at Publisher · View at Google Scholar · View at Scopus
  25. Z.-W. Chen, Z.-X. Wu, H.-X. Sang et al., “Effect of aspirin administration for the treatment of osteoporosis in ovariectomized rat model,” Zhonghua yi xue za zhi, vol. 91, no. 13, pp. 925–929, 2011. View at Google Scholar · View at Scopus
  26. S. E. Lin, J. P. Huang, L. Z. Wu, T. Wu, and L. Cui, “Prevention of osteopenia and dyslipidemia in rats after ovariectomy with combined aspirin and low-dose diethylstilbestrol,” Biomedical and Environmental Sciences, vol. 26, no. 4, pp. 249–257, 2013. View at Publisher · View at Google Scholar · View at Scopus
  27. J. Wei, J. Wang, Y. Gong, and R. Zeng, “Effectiveness of combined salmon calcitonin and aspirin therapy for osteoporosis in ovariectomized rats,” Molecular Medicine Reports, vol. 12, no. 2, pp. 1717–1726, 2015. View at Publisher · View at Google Scholar
  28. R. T. Turner, A. Maran, S. Lotinun et al., “Animal models for osteoporosis,” Reviews in Endocrine and Metabolic Disorders, vol. 2, no. 1, pp. 117–127, 2001. View at Publisher · View at Google Scholar · View at Scopus
  29. S. Reagan-Shaw, M. Nihal, and N. Ahmad, “Dose translation from animal to human studies revisited,” FASEB Journal, vol. 22, no. 3, pp. 659–661, 2008. View at Publisher · View at Google Scholar · View at Scopus
  30. D. C. Bauer, E. S. Orwoll, K. M. Fox et al., “Aspirin and NSAID use in older women: effect on bone mineral density and fracture risk,” Journal of Bone and Mineral Research, vol. 11, no. 1, pp. 29–35, 1996. View at Google Scholar · View at Scopus
  31. P. Vestergaard, P. Hermann, J.-E. B. Jensen, P. Eiken, and L. Mosekilde, “Effects of paracetamol, non-steroidal anti-inflammatory drugs, acetylsalicylic acid, and opioids on bone mineral density and risk of fracture: results of the danish osteoporosis prevention study (dops),” Osteoporosis International, vol. 23, no. 4, pp. 1255–1265, 2012. View at Publisher · View at Google Scholar · View at Scopus
  32. L. D. Carbone, F. A. Tylavsky, J. A. Cauley et al., “Association between bone mineral density and the use of nonsteroidal anti-inflammatory drugs and aspirin: impact of cyclooxygenase selectivity,” Journal of Bone and Mineral Research, vol. 18, no. 10, pp. 1795–1802, 2003. View at Publisher · View at Google Scholar · View at Scopus
  33. P. Vestergaard, T. H. Steinberg, P. Schwarz, and N. R. Jørgensen, “Use of the oral platelet inhibitors dipyridamole and acetylsalicylic acid is associated with increased risk of fracture,” International Journal of Cardiology, vol. 160, no. 1, pp. 36–40, 2012. View at Publisher · View at Google Scholar · View at Scopus
  34. I. Konstantinidis, S. N. Papageorgiou, A. Kyrgidis, T.-G. Tzellos, and D. Kouvelas, “Effect of non-steroidal anti-inflammatory drugs on bone turnover: an evidence-based review,” Reviews on Recent Clinical Trials, vol. 8, no. 1, pp. 48–60, 2013. View at Publisher · View at Google Scholar · View at Scopus
  35. C. Liu, X. Zhang, M. Wu, and L. You, “Mechanical loading up-regulates early remodeling signals from osteocytes subjected to physical damage,” Journal of Biomechanics, vol. 48, no. 16, pp. 4221–4228, 2015. View at Publisher · View at Google Scholar · View at Scopus
  36. B. L. Riggs, S. Khosla, and L. J. Melton III, “Sex steroids and the construction and conservation of the adult skeleton,” Endocrine Reviews, vol. 23, no. 3, pp. 279–302, 2002. View at Publisher · View at Google Scholar · View at Scopus
  37. D. Aslan, M. D. Andersen, L. B. Gede et al., “Mechanisms for the bone anabolic effect of parathyroid hormone treatment in humans,” Scandinavian Journal of Clinical and Laboratory Investigation, vol. 72, no. 1, pp. 14–22, 2012. View at Publisher · View at Google Scholar · View at Scopus